Advisors

Reviva’s advisory board consists of highly successful, experienced and qualified professionals associated with Pharmaceutical and medical industries.

Daphne Karydas

Daphne

Daphne Karydas is currently serving as our Chief Financial Officer for Syndex. Ms. Karydas previously served as Senior Vice President of Corporate Financial Planning & Analysis and Strategy at Allergan plc, where she oversaw the company’s long-term financial and business strategy, until its recent acquisition by Abbvie in May 2020. She joined Allergan in April 2017 as Senior Vice President of Global Investor Relations and Strategy at Allergan, leading engagement with the investment community and business strategy development. 

Prior to joining Allergan, she served as Executive Director and Senior Healthcare Analyst at J.P. Morgan Asset Management. Previously, she was a Portfolio Manager and Senior Healthcare Analyst at The Boston Company Asset Management, a BNY Mellon company. Earlier, Ms. Karydas was a Vice President at Goldman Sachs Asset Management focused on healthcare, as well as a member of Goldman Sachs’ healthcare investment banking team. Before joining Goldman Sachs, she was a Project Chemical Engineer at Merck & Co. where she focused on process development for novel vaccines. 

Ms. Karydas received a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
 

John M. Kane, MD

kane

John M. Kane, MD is currently serving as Senior Vice President of Behavioral Health Services at Northwell Health. He is Chair of Psychiatry at both the Zucker Hillside Hospital as well as the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health.

In addition to having oversight for system-wide behavioral health services as well as academic, research and clinical programs at Northwell Health’s psychiatric hospital, John Kane, MD, directs the National Institute of Mental Health (NIMH)-funded Advanced Center for Interventions and Services Research in Schizophrenia at Zucker Hillside Hospital.

Dr. Kane has been a member of the Board of Scientific Counselors for NIMH, and has served on the council of the American College of Neuropsychopharmacology. He has chaired the NIMH Psychopathology and Psychobiology Review Committee, as well as the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration.

Dr. Kane holds the Dr. E. Richard Feinberg Chair in Schizophrenia Research at the Albert Einstein College of Medicine. He is a recipient of the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award for Research, the American Psychiatric Foundation’s Fund Prize for Research, the Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.

Dr. Kane received his medical degree from New York University School of Medicine.

Leslie Citrome, MD

Leslie

Leslie Citrome, M.D. is a Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation.

Dr. Citrome is a member of the Board of Directors, Treasurer, and President-Elect of the American Society of Clinical Psychopharmacology. Main areas of interest include schizophrenia, bipolar disorder and major depressive disorder. He is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm.

Dr. Citrome is the author or co-author of over 500 research reports, reviews, and book chapters in the scientific literature, is on the editorial board of 11 different medical journals, Editor Emeritus at the International Journal of Clinical Practice and where he served as Editor in Chief from 2013 through 2019, reviews for over 75 other journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.

Martin Kolb, MD, PhD

Martin

Martin Kolb, MD, PhD is an associate professor of medicine and director of research for the Firestone Institute for Respiratory Health at St. Joseph's Healthcare. He trained with Dr. Jack Gauldie at McMaster University from 1999-2001 and they closely collaborate since then on basic and translational projects in pulmonary fibrosis. Dr. Kolb runs a specialty clinic for interstitial lung diseases and pulmonary fibrosis at St. Joseph's Healthcare and is involved as Principal Investigator and Steering Committee member in several multi-center trials for lung fibrosis.

Dr. Kolb has published more than 80 scientific articles and is Deputy Editor for Respirology and on the Editorial Board of the American Journal of Respiratory and Critical Care Medicine.

He obtained his MD from the University of Würzburg, Germany in 1991, where he also completed a PhD equivalent in Experimental Respirology in 2003.

Roham Zamanian, MD

Roham

Roham Zamanian, MD is an Associate Professor of Medicine and Director of the Adult Pulmonary Hypertension Program at Stanford University School of Medicine. Dr. Zamanian completed his medical school and residency at the University of California, Irvine Medical Center and moved to Stanford University for a fellowship in pulmonary and critical care medicine. Dr. Zamanian extended his training by completing the eBay Pulmonary Vascular Disease super-fellowship at the Vera Moulton Wall Center (VMWC) for Pulmonary Vascular Diseases at Stanford University.

After completing training, he joined the faculty of the Division of Pulmonary & Critical Care and Vera Moulton Wall Center for Pulmonary Vascular Disease and in 2007 was selected as the Director of the Adult Pulmonary Hypertension Program - a rare-disease program which has grown to include seven attending physicians, 2 PH post-doctoral fellows, 4 advanced care practitioners, and 6 clinical and research staff. The Stanford Adult Pulmonary Hypertension Program evaluates and treats approximately 600-700 PH patients annually.

Besides an active clinical career, Dr. Zamanian is extensively engaged in clinical translational research. He currently directs the Vera Moulton Wall Center clinical database and biobank and focuses his research on clinical characterization and impact of novel risk factors such as methamphetamine use, and biomarkers, such as insulin resistance, in pulmonary arterial hypertension. Beyond industry clinical trials and registries, Dr. Zamanian has re-focused the research mission of the Stanford PH program by collaborating with basic science faculty and implementing several proof-of-concept and Phase I and II clinical trials of novel therapeutics developed at Stanford University. Dr. Zamanian's research is currently funded by multiple grants from the National Institutes of Health and the VMWC.